Consistent with the observed anti-fibrotic activity of KX-01, the dual-specificity Src/Abl family kinase inhibitor saracatinib has been granted orphan drug designation by the FDA for the treatment of IPF. Here, SRC is linked to idiopathic pulmonary fibrosis.